Intervention, interventional group characteristics, and duration of studies exploring the efficacy of SGLT-2 inhibitors in patients with concurrent type 2 diabetes mellitus and non-alcoholic fatty liver disease. This evidence concerns the gene SLC5A2 and diabetes mellitus.